Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
NCT ID: NCT01110720
Last Updated: 2013-01-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
313 participants
INTERVENTIONAL
2010-10-31
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)
NCT04993768
RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY
NCT04937530
A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)
NCT04185415
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
NCT04777331
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Davunetide 30 mg BID
Davunetide
Davunetide Nasal Spray 30 mg BID IN 52 weeks
Placebo
Davunetide
Davunetide Nasal Spray 30 mg BID IN 52 weeks
Placebo
Placebo Nasal Spray BID IN 52 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Davunetide
Davunetide Nasal Spray 30 mg BID IN 52 weeks
Placebo
Placebo Nasal Spray BID IN 52 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* at least a 12-month history of postural instability or falls during the first 3 years that symptoms are present; and
* at screening, a decreased downward saccade velocity defined as observable eye movement (deviation from the "main sequence" linear relationship between saccade amplitude and saccade velocity) or, supranuclear ophthalmoplegia defined as 50% reduction in upward gaze or 30% reduction in downward gaze; and
* age at symptom onset of 40 to 85 years by history; and
* an akinetic-rigid syndrome with prominent axial rigidity.
* Aged 41 to 85 years at the time of screening.
* Judged by investigator to be able to comply with neuropsychological evaluation at baseline and throughout the study.
* Must have reliable caregiver accompany subject to all study visits. Caregiver must read, understand, and speak local language fluently to ensure comprehension of informed consent form and informant-based assessments of subject. Caregiver must also have frequent contact with subject (at least 3 hours per week at one time or at different times) and be willing to monitor study medication compliance and the subject's health and concomitant medications throughout the study.
* Modified Hachinski score ≤ 3 (Appendix 7). This modified Hachinski will not include the focal neurological signs, symptoms or pseudobulbar affect questions, given the prominence of all 3 in PSP.
* Score ≥ 15 on the mini-mental state examination (MMSE) at screening (Visit 1).
* Written informed consent provided by subject (or legally-appointed representative, as appropriate) and caregiver (if not the legally-appointed representative) who are both fluent local language speakers.
* Subject resides outside a skilled nursing facility or dementia care facility at the time of screening, and admission to such a facility is not planned. Residence in an assisted living facility is allowed.
* If the subject is receiving levodopa/carbidopa, levodopa/benserazide, a dopamine agonist, catechol-o-methyltransferase (COMT) inhibitor, or other Parkinson's medication,with teh exception of Azilect(rasagiline), the dose must have been stable for at least 60 days prior to the screening visit (Visit 1) and must remain stable for the duration of the study. No such medication can be initiated during the study. Subjects receiving rasagiline or CoQ10 must be on a stable dose for at least 90 days prior to the screening visit.
* Able to tolerate the MRI scan during screening with either no sedation or low dose lorazepam.
* Able to ambulate independently or with assistance defined as the ability to take at least 5 steps with a walker (guarding is allowed provided there is no contact) or the ability to take at least 5 steps with the assistance of another person who can only have contact with one upper extremity.
* Presence of symptoms for less than 5 years or the presence of symptoms for more than 5 years with a PSPRS baseline score ≥ 40.
* Stable on all other chronic medications for at least 30 days prior to the screening visit (Visit 1).
* Cerebellar ataxia,
* Choreoathetosis,
* Early, symptomatic autonomic dysfunction; or
* Tremor while at rest.
* Presence of other significant neurological or psychiatric disorders including (but not limited to) Alzheimer's disease; dementia with Lewy bodies; prion disease; Parkinson's disease (which has not subsequently been revised to PSP); any psychotic disorder; severe bipolar or unipolar depression; seizure disorder; tumor or other space-occupying lesion; or history of stroke or head injury with loss of consciousness for at least 15 minutes within the past 20 years.
* Within 4 weeks of screening or during the course of the study, concurrent treatment with memantine; acetylcholinesterase inhibitors; antipsychotic agents (other than quetiapine) or mood stabilizers (e.g., valproate, lithium); or benzodiazepines (except as below).
* Low dose lorazepam (not more than 2 mg) may be used for sedation prior to MRI scans for those subjects requiring sedation. Neuropsychological testing may not be performed after lorazepam administration.
* Subjects who take short acting benzodiazepines (only temazepam or zolpidem are allowed) for sleep may continue to do so if they have been on a stable dose for 30 days prior to screening.
* Clonazepam may be used for treatment of dystonia or painful rigidity associated with PSP if the dose has been stable for 90 days prior to screening and is not expected to change during the course of the study.
* Treatment with lithium, methylene blue, tramiprosate, ketone bodies, latrepirdine, or any putative disease-modifying agent directed at tau within 90 days of screening.
* A history of alcohol or substance abuse within 1 year prior to screening and deemed to be clinically significant by the site investigator.
* Any malignancy (other than non-metastatic dermatological conditions) within 5 years of the screening visit (Visit 1) or current clinically significant hematological, endocrine, cardiovascular, renal, hepatic, gastrointestinal, or neurological disease. For the non-cancer conditions, if the condition has been stable for at least one year before the screening visit and is judged by the site investigator not to interfere with the subject's participation in the study, the subject may be included.
* Clinically significant laboratory abnormalities at screening, including creatinine ≥ 2.5 mg/dL, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3 times the upper limit of the normal reference range, vitamin B12 below the laboratory normal reference range, or thyroid stimulating hormone TSH above laboratory normal reference range.
* The systolic blood pressure measurement is \> 190 or \< 85 mm Hg. The diastolic blood pressure measurement is \> 105 or \< 50 mm Hg at screening.
* Abnormal ECG tracing at screening and judged to be clinically significant by the site investigator.
* Treatment with any investigational drugs or device within 90 days of screening.
* Known history of serum or plasma progranulin level less than one standard deviation below the normal subject mean for the laboratory performing the assay.
* Known presence of known disease-associated mutation in TDP-43, PGRN, CHMPB2, or VCP genes or any other frontotemporal lobar degeneration (FTLD) causative genes not associated with underlying tau pathology (e.g., Chromosome 9 associated FTD).
* History of deep brain stimulator (DBS) surgery other than sham surgery for DBS clinical trial.
* History of early, prominent rapid eye movement (REM) sleep behavior disorder.
* Women who are pregnant or lactating and women of childbearing potential who are not using at least two different forms of medically recognized and highly effective methods of birth control, resulting in a low failure rate when used consistently and correctly such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner.
* An employee or relative of an employee of the Sponsor, a clinical site, or Contract Research Organization participating in the study.
* Significant anatomical nasal abnormality (e.g., septal deviation obstructing airflow to at least one nostril or septal perforation) or history of nasal turbinate surgery.
* History of a clinically significant medical condition that would interfere with the subject's ability to comply with study instructions, would place the subject at increased risk, or might confound the interpretation of the study results.
* Contraindication to MRI examination for any reason (e.g., severe claustrophobia, ferromagnetic metal in body).
* Structural abnormality on MRI that precludes diagnosis of PSP, such as cortical infarct in brain region that might account for subject's symptoms.
* In subjects receiving anti-Parkinson's Disease medication at the time of screening, in the opinion of the investigator substantial worsening of motor signs or symptoms compared with normal functioning following overnight withdrawal of the anti-Parkinson medication.
* Known hypersensitivity to davunetide or any ingredient of the formulation.
Exclusion Criteria
* A diagnosis of Amyotrophic Lateral Sclerosis or other motor neuron disease.
* Any of the following:
41 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allon Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adam Boxer, M.D., PhD.
Role: PRINCIPAL_INVESTIGATOR
Memory and Aging Center, University of California, San Francisco
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama - Birmingham
Birmingham, Alabama, United States
Muhammed Ali Parkinson Center and Movement Disorders Clinic
Phoenix, Arizona, United States
Mayo Clinic, AZ
Scottsdale, Arizona, United States
USC Keck School of Medicine
Los Angeles, California, United States
David Geffen School of Medicine - UCLA
Los Angeles, California, United States
UCSD/VA Neurology Service
San Diego, California, United States
UCSF Memory and Aging Center
San Francisco, California, United States
Colorado Neurological Institute - Rocky Mountain Movement Disorders Ctr, PC
Englewood, Colorado, United States
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida, United States
Mayo Clinic, Florida
Jacksonville, Florida, United States
The Frances J. Zesiewicz Foundation for Parkinson's Disease at USF
Tampa, Florida, United States
University of Chicago Medical Center
Chicago, Illinois, United States
University of Kansas Medical Center Parkinson Disease & Movement Disorders Center
Kansas City, Kansas, United States
University of Louisville Division of Movement Disorders
Louisville, Kentucky, United States
John Hopkins Hospital
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Lahey Clinic
Burlington, Massachusetts, United States
University of Michigan Medical Center
Ann Arbor, Michigan, United States
University of Minnesota Department of Neuology
Minneapolis, Minnesota, United States
Mayo Clinic, Rochester, MN
Rochester, Minnesota, United States
UMDNJ - Robert Wood Johnson Medical Center
New Brunswick, New Jersey, United States
Columbia University
New York, New York, United States
Univeristy of North Carolina Department of Neurology
Chapel Hill, North Carolina, United States
University Hospitals Case Medical CenterNI Movement Disorders Center
South Euclid, Ohio, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Baylor College of Medicine
Houston, Texas, United States
University of Utah Center for Alzheimer's Care, Imaging &Research
Salt Lake City, Utah, United States
The Alfred Hospital
Melbourne, Victoria, Australia
London Sciences Health Center University Hospital
London, Ontario, Canada
Parkinson's Disease & Movement Disorders Clinic
Ottawa, Ontario, Canada
Toronto Western Hospital University Health Network
Toronto, Ontario, Canada
CHUM-Notre Dame Hospital Unité de Troubles du Mouvement
Montreal, Quebec, Canada
McGill University Health Centre - Montreal General Hospital
Montreal, Quebec, Canada
Limoges University Hospital
Limoges, , France
Hopital Timone
Marseille, , France
Hôpitaux de Paris
Paris, , France
Humboldt University Charité
Berlin, , Germany
Neurologisch Klinik der Ruhr-Universität im St. Josef-Hospital
Bochum, , Germany
Universitätsklinikum Carl Carus an der Technischen Universität
Dresden, , Germany
Paracelsus-Elena Klinik
Kassel, , Germany
Philipps Universität Marburg
Marburg, , Germany
Klinikum Großhadern
München, , Germany
Universität Rostock Zentrum für Nervenheilkunde und Poliklinik
Rostock, , Germany
Universitäts- und Rehabilitationskliniken Ulm
Ulm, , Germany
Princess Royal Hospital
Haywards Heath, , United Kingdom
Clinical Ageing Research Unit (CARU) Newcastle University
Newcastle, , United Kingdom
Greater Manchester Neuroscience Centre
Salford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hoglinger GU, Schope J, Stamelou M, Kassubek J, Del Ser T, Boxer AL, Wagenpfeil S, Huppertz HJ; AL-108-231 Investigators; Tauros MRI Investigators; Movement Disorder Society-Endorsed PSP Study Group. Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials. Mov Disord. 2017 Jun;32(6):842-852. doi: 10.1002/mds.26973. Epub 2017 Apr 24.
Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, Roberson ED, Hoglinger GU, Koestler M, Jack CR Jr, Van Deerlin V, Randolph C, Lobach IV, Heuer HW, Gozes I, Parker L, Whitaker S, Hirman J, Stewart AJ, Gold M, Morimoto BH; AL-108-231 Investigators. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul;13(7):676-85. doi: 10.1016/S1474-4422(14)70088-2. Epub 2014 May 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AL-108-231
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.